Aptorum Group’s Subsidiary - Claves Life Sciences Limited Establishes Novel Therapeutic Platform for Treatment of Various D...
May 06 2019 - 8:00AM
Business Wire
Claves Life Sciences Limited, a wholly owned subsidiary of
Aptorum Group Limited ("Aptorum") (Nasdaq: APM), is excited to
announce the establishment of a novel therapeutic platform for the
treatment of various diseases via modulation of the chemical
signaling relating to gut microbiota. The role of gut microbiota in
the pathogenesis of various diseases has been under the spotlight
recently. It has been demonstrated that gut microbiota is related
to major diseases such as metabolic and cardiovascular diseases1,2,
cancer3, neurodegenerative diseases4, etc.
“With the continuous discovery of the role played by gut
microbiota in various diseases, we believe that novel therapeutic
targets will be subsequently identified and defined. As a result,
we believe that the therapeutic potential of our platform is
unlimited at present and for the future", expressed by Mr. Ian
Huen, the CEO of Aptorum. Through our collaboration with local
universities, our initial focus is currently on metabolic and
cardiovascular diseases. We are targeting to move our drug
candidates to Ph 1 clinical trial by 2020 - 2021.
1Nature Communications 8: 845 (2017)
2BMB Rep. 2016 Oct 31; 49(10): 536–541
3https://www.bloomberg.com/news/articles/2016-03-14/how-gut-bacteria-are-shaking-up-cancer-research
4https://www.bbc.com/news/health-46050744
About Aptorum Group Limited
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company
dedicated to developing and commercializing a broad range of
therapeutic and diagnostic technologies to tackle unmet medical
needs. Aptorum Group is pursuing therapeutic and diagnostic
projects in neurology, infectious diseases, gastroenterology,
oncology and other disease areas as well as non-therapeutic areas
such as surgical robotics and the operations of its medical clinic
in Hong Kong, Talem Medical, with the initial focus on treatment of
chronic diseases resulting from modern sedentary lifestyles and
aging population.
For more information about Aptorum Group, please visit
www.aptorumgroup.com.
About Claves Life Sciences Limited
Claves Life Sciences Limited is a wholly-owned therapeutics
subsidiary of Aptorum Group Limited. Claves focuses on the clinical
development in therapeutic candidates related to the field of
gastroenterology. The potential candidates under review and
potentially developed focus on the modulation of gut microbiota
derived metabolites, for preventing or treating diseases. Claves is
also exploring a gut microbiota modulation platform that can
generate novel custom candidates capable of fine-tuning levels of
gut metabolites, potentially treating a wide range of medical
conditions.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum
Group Limited and its future expectations, plans and prospects that
constitute “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as “may,” “should,” “expects,” “plans,” “anticipates,”
“could,” “intends,” “target,” “projects,” “contemplates,”
“believes,” “estimates,” “predicts,” “potential,” or “continue,” or
the negative of these terms or other similar
expressions. Aptorum Group has based these forward-looking
statements largely on its current expectations and projections
about future events and trends that it believes may affect its
business, financial condition and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of risks, uncertainties and
assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, the company’s anticipated growth
strategies, anticipated trends and challenges in its business, and
its expectations regarding, and the stability of, its supply chain,
and the risks more fully described in Aptorum Group’s Form
20-F and other filings that Aptorum Group may make
with the SEC in the future. Aptorum Group
assumes no obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190506005342/en/
Investors:Tel: +852 2117 6611Email:
investor.relations@aptorumgroup.comMedia:Tel: + 852 2117 6611Email:
info@aptorumgroup.com
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aptorum (NASDAQ:APM)
Historical Stock Chart
From Apr 2023 to Apr 2024